Lead Sponsor

Sanofi

Age

12 - No limit years

Sex

ALL

Healthy Volunteers

No

•Participants greater than or equal to (\>=) 12 years of age inclusive, at the time of signing the informed consent.
•Disease location amenable to tumor biopsy at Baseline.
•Measurable disease.
•For Cohort A1 (cHL anti-programmed cell death protein 1/ligand 1 \[PD-1/PD-L1\] inhibitor naïve): Histologically confirmed advanced cHL that had relapsed or progressed after at least 3 lines of systemic therapy that included autologous hematopoietic stem cell transplant (auto-HSCT) or auto-HSCT and brentuximab vedotin (BV).
•For Cohort A2 (cHL anti-PD-1/PD-L1 inhibitor progressor): Histologically confirmed advanced cHL which had relapsed or progressed after one previous anti-PD-1/PD-L1 containing regimen as the most recent prior therapy but no more than 4 lines of previous chemotherapy including the anti-PD-1/PD-L1 containing regimen and documentation of benefit during or after the anti-PD-1/PD-L1 containing regimen within 4 months prior to initiation of investigational medicinal product.

•For Cohort C (peripheral T-cell lymphoma \[PTCL\]): Histologically confirmed advanced PTCL that had relapsed or progressed after either first-line chemotherapy and auto-HSCT as consolidation of first remission or first-line chemotherapy if participants were ineligible for auto-HSCT.
•Body weight of greater than (\>) 45 kilograms for participants with age less than (\<)18 years.
•Prior exposure to agent that blocks CD38.
•For participants with cHL (PD-1/PD-L1 naïve), DLBCL or PTCL prior exposure to any agent (approved or investigational) that blocks the PD-1/PD-L1, PD-L2, CD137, cytotic T-lymphocyte-associated protein 4 or LAG-3.
•Evidence of other immune related disease/conditions.
•Had received a live-virus vaccination within 28 days of planned treatment start; seasonal flu vaccines that do not contain live virus are permitted.
•Eastern Cooperative Oncology Group (ECOG) performance status (PS) \>=2.
•Poor bone marrow reserve.
•Poor organ function.
•The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Related studies

NCT06395103 · B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, and more

NCT05100862 · Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma

NCT04728893 · Hematologic Malignancies, Waldenstroms Macroglobulinaemia, and more

NCT06678659 · Unresectable, Locally Advanced, and more

NCT06191744 · Follicular Lymphoma (FL)

A Study of Isatuximab-based Therapy in Participants With Lymphoma